sing metabolism and allowing
the body to continue losing weight by offsetting its natural tendency to fight
back and slow down the weight loss process. Contrave is being studied in four
Phase 3 trials, all of which have completed enrollment. We expect to provide
results from all four Phase 3 trials by mid-2009. We remain on target to file
a New Drug Application (NDA) with the FDA in late 2009.
About Orexigen(R) Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead combination product candidates
targeted for obesity are Contrave, which is in Phase 3 clinical trials, and
Empatic(TM), which is in the later stages of Phase 2 clinical development.
Each product candidate is designed to act on a specific group of neurons in
the central nervous system with the goal of achieving appetite suppression and
sustained weight loss. Further information about the company can be found at
Orexigen cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects," "indicates,"
"will," "intends," "potential," "suggests," "assuming," "designed," "projects"
and similar expressions are intended to identify forward-looking statements.
These statements are based on the Company's current beliefs and expectations.
These forward-looking statements include statements regarding enrollment,
timing, execution and completion of clinical trials of Contrave, the timing of
an NDA submission with the FDA for Contrave, the efficacy and safety of
Contrave, the potential to obtain regulatory approval for, and effectively
treat obesity with, Contrave, and the potential issuance of patents and the
scope and duration of p
Page: 1 2 3 Related biology technology :1
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-0032
. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 20083
. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences4
. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders5
. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain6
. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results7
. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA8
. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review9
. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation10
. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway11
. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007